Is Labcorp Holdings (LH) Fully Priced Following Oncology Approvals And Raised Outlook?

Labcorp Holdings (LH) is in focus after a series of oncology diagnostics approvals and launches, including the PGDx elio tissue complete CDx for advanced melanoma and nationwide access to Roche's VENTANA PTEN RxDx Assay for prostate cancer. See our latest analysis for Labcorp Holdings. Labcorp Holdings has attracted more attention in recent months, with oncology diagnostics approvals and stronger earnings updates sitting alongside a 30 day share price return of 16.48% and a 1 year total...